Compare · RAIN vs TMO
RAIN vs TMO
Side-by-side comparison of Rain Enhancement Technologies Holdco Inc. (RAIN) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- RAIN operates in Technology, while TMO operates in Industrials - the two are in different parts of the market.
- TMO is the larger of the two at $197.88B, about 12414.0x RAIN ($15.9M).
- TMO has been more active in the news (9 items in the past 4 weeks vs 6 for RAIN).
- TMO has more recent analyst coverage (25 ratings vs 8 for RAIN).
- Company
- Rain Enhancement Technologies Holdco Inc.
- Thermo Fisher Scientific Inc
- Price
- -
- -
- Market cap
- $15.9M
- $197.88B
- 1M return
- -
- +12.59%
- 1Y return
- -
- +28.12%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 6
- 9
- Recent ratings
- 8
- 25
Rain Enhancement Technologies Holdco Inc.
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is RAIN-32, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing RAIN-32 that has completed Phase II clinical trial in liposarcoma, Phase I clinical trial in solid tumors, and Phase II clinical trial in intimal sarcoma, as well as RAD52 for tumors, including breast, ovarian, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest RAIN
- SEC Form EFFECT filed by Rain Enhancement Technologies Holdco Inc.
- Rain Enhancement Technologies Holdco Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 424B5 filed by Rain Enhancement Technologies Holdco Inc.
- Amendment: SEC Form S-3/A filed by Rain Enhancement Technologies Holdco Inc.
- Rain Enhancement Technologies Holdco Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form S-3 filed by Rain Enhancement Technologies Holdco Inc.
- Director Riley Christopher Michael was granted 50,000 shares (SEC Form 4)
- Director Sylvester David C was granted 40,000 shares (SEC Form 4)
- Director Steele Alexandra was granted 80,000 shares (SEC Form 4)
- Director Dickerson Lyman B was granted 80,000 shares, increasing direct ownership by 781% to 90,247 units (SEC Form 4)
Latest TMO
- Thermo Fisher Scientific Announces Quarterly Dividend
- Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, July 23, 2026
- SEC Form 4 filed by Director Sperling Scott M
- SEC Form 4 filed by Director Keith R. Alexandra
- SEC Form 4 filed by Director Weisler Dion J
- SEC Form 4 filed by Director Lynch Karen S
- SEC Form 4 filed by Director Johnson Jennifer M
- Bernstein resumed coverage on Thermo Fisher with a new price target
- SEC Form 11-K filed by Thermo Fisher Scientific Inc
- Piper Sandler initiated coverage on Thermo Fisher with a new price target